Woodstock Corp lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 16.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,282 shares of the company’s stock after buying an additional 764 shares during the quarter. Woodstock Corp’s holdings in Eli Lilly and were worth $987,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its position in shares of Eli Lilly and by 51.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,094,613 shares of the company’s stock worth $2,042,017,000 after buying an additional 4,082,728 shares during the period. Norges Bank purchased a new stake in shares of Eli Lilly and in the 4th quarter worth about $1,463,293,000. Janus Henderson Group PLC grew its position in shares of Eli Lilly and by 5.2% in the 4th quarter. Janus Henderson Group PLC now owns 6,124,921 shares of the company’s stock worth $1,034,108,000 after buying an additional 302,296 shares during the period. Fisher Asset Management LLC grew its position in shares of Eli Lilly and by 7.7% in the 4th quarter. Fisher Asset Management LLC now owns 5,037,790 shares of the company’s stock worth $850,580,000 after buying an additional 359,479 shares during the period. Finally, California Public Employees Retirement System grew its position in shares of Eli Lilly and by 2.5% in the 4th quarter. California Public Employees Retirement System now owns 4,575,362 shares of the company’s stock worth $772,504,000 after buying an additional 110,280 shares during the period. 75.59% of the stock is currently owned by hedge funds and other institutional investors.

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction that occurred on Wednesday, January 13th. The shares were sold at an average price of $185.97, for a total value of $39,053,700.00. Following the transaction, the insider now owns 110,807,418 shares in the company, valued at approximately $20,606,855,525.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 555,284 shares of company stock worth $106,132,302 in the last quarter. Company insiders own 0.09% of the company’s stock.

LLY traded up $0.74 during midday trading on Thursday, hitting $183.06. 17,789 shares of the company traded hands, compared to its average volume of 4,374,581. The company’s 50-day moving average is $195.68 and its 200 day moving average is $171.39. Eli Lilly and Company has a 52 week low of $129.21 and a 52 week high of $218.00. The company has a quick ratio of 1.06, a current ratio of 1.36 and a debt-to-equity ratio of 3.27. The firm has a market capitalization of $175.55 billion, a PE ratio of 29.79, a price-to-earnings-growth ratio of 1.57 and a beta of 0.37.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Thursday, January 28th. The company reported $2.75 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.35 by $0.40. Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The firm had revenue of $7.44 billion for the quarter, compared to analysts’ expectations of $7.27 billion. During the same quarter in the prior year, the business earned $1.73 EPS. The business’s quarterly revenue was up 21.7% on a year-over-year basis. On average, sell-side analysts predict that Eli Lilly and Company will post 7.56 earnings per share for the current fiscal year.

A number of equities analysts recently issued reports on LLY shares. Cowen upped their price target on shares of Eli Lilly and from $195.00 to $235.00 and gave the stock an “outperform” rating in a research note on Friday, February 12th. Mizuho upped their price target on shares of Eli Lilly and from $222.00 to $228.00 and gave the stock a “buy” rating in a research note on Monday, February 1st. Wolfe Research upgraded shares of Eli Lilly and from a “peer perform” rating to an “outperform” rating and upped their price target for the stock from $147.00 to $183.00 in a research note on Thursday, December 10th. Truist Securities upped their price target on shares of Eli Lilly and from $215.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, March 22nd. Finally, Truist upped their price target on shares of Eli Lilly and from $200.00 to $215.00 in a research note on Monday, February 1st. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $193.88.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Story: How to invest using market indexes

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.